BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22855598)

  • 1. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.
    Vasmatzis G; Johnson SH; Knudson RA; Ketterling RP; Braggio E; Fonseca R; Viswanatha DS; Law ME; Kip NS; Ozsan N; Grebe SK; Frederick LA; Eckloff BW; Thompson EA; Kadin ME; Milosevic D; Porcher JC; Asmann YW; Smith DI; Kovtun IV; Ansell SM; Dogan A; Feldman AL
    Blood; 2012 Sep; 120(11):2280-9. PubMed ID: 22855598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.
    Boddicker RL; Razidlo GL; Dasari S; Zeng Y; Hu G; Knudson RA; Greipp PT; Davila JI; Johnson SH; Porcher JC; Smadbeck JB; Eckloff BW; Billadeau DD; Kurtin PJ; McNiven MA; Link BK; Ansell SM; Cerhan JR; Asmann YW; Vasmatzis G; Feldman AL
    Blood; 2016 Sep; 128(9):1234-45. PubMed ID: 27297792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma.
    Aubry MC; Roden A; Murphy SJ; Vasmatzis G; Johnson SH; Harris FR; Halling G; Knudson RA; Ketterling RP; Feldman AL
    Mod Pathol; 2015 Mar; 28(3):359-66. PubMed ID: 25189640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
    Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH
    Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay.
    Drieux F; Ruminy P; Sater V; Marchand V; Fataccioli V; Lanic MD; Viennot M; Viailly PJ; Sako N; Robe C; Dupuy A; Vallois D; Veresezan L; Poullot E; Picquenot JM; Bossard C; Parrens M; Lemonnier F; Jardin F; de Leval L; Gaulard P
    J Mol Diagn; 2021 Aug; 23(8):929-940. PubMed ID: 34147695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.
    Si H; Lu H; Yang X; Mattox A; Jang M; Bian Y; Sano E; Viadiu H; Yan B; Yau C; Ng S; Lee SK; Romano RA; Davis S; Walker RL; Xiao W; Sun H; Wei L; Sinha S; Benz CC; Stuart JM; Meltzer PS; Van Waes C; Chen Z
    Oncogene; 2016 Nov; 35(44):5781-5794. PubMed ID: 27132513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.
    Møller MB; Ino Y; Gerdes AM; Skjødt K; Louis DN; Pedersen NT
    Leukemia; 1999 Mar; 13(3):453-9. PubMed ID: 10086736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).
    Ohki K; Kiyokawa N; Watanabe S; Iwafuchi H; Nakazawa A; Ishiwata K; Ogata-Kawata H; Nakabayashi K; Okamura K; Tanaka F; Fukano R; Hata K; Mori T; Moriya Saito A; Hayashi Y; Taga T; Sekimizu M; Kobayashi R;
    Br J Haematol; 2021 Aug; 194(4):718-729. PubMed ID: 34258755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.
    Wang X; Boddicker RL; Dasari S; Sidhu JS; Kadin ME; Macon WR; Ansell SM; Ketterling RP; Rech KL; Feldman AL
    Hum Pathol; 2017 Jun; 64():19-27. PubMed ID: 28153507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.
    Grønbaek K; Worm J; Ralfkiaer E; Ahrenkiel V; Hokland P; Guldberg P
    Blood; 2002 Aug; 100(4):1430-7. PubMed ID: 12149228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
    Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
    Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive peripheral T-cell lymphomas (specified and unspecified types).
    Savage KJ
    Hematology Am Soc Hematol Educ Program; 2005; ():267-77. PubMed ID: 16304391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STX11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas.
    Yoshida N; Tsuzuki S; Karube K; Takahara T; Suguro M; Miyoshi H; Nishikori M; Shimoyama M; Tsukasaki K; Ohshima K; Seto M
    Cancer Sci; 2015 Oct; 106(10):1455-62. PubMed ID: 26176172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy.
    Salah Z; Bar-mag T; Kohn Y; Pichiorri F; Palumbo T; Melino G; Aqeilan RI
    Cell Death Dis; 2013 Jan; 4(1):e480. PubMed ID: 23370280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features.
    Balagué O; Martínez A; Colomo L; Roselló E; Garcia A; Martínez-Bernal M; Palacín A; Fu K; Weisenburger D; Colomer D; Burke JS; Warnke RA; Campo E
    Am J Surg Pathol; 2007 Sep; 31(9):1310-22. PubMed ID: 17721185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
    Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
    J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
    Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
    Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma.
    Scott DW; Mungall KL; Ben-Neriah S; Rogic S; Morin RD; Slack GW; Tan KL; Chan FC; Lim RS; Connors JM; Marra MA; Mungall AJ; Steidl C; Gascoyne RD
    Blood; 2012 May; 119(21):4949-52. PubMed ID: 22496164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.
    Zhang LL; Pan HX; Wang YX; Guo T; Liu L
    Int J Oncol; 2019 Nov; 55(5):1077-1089. PubMed ID: 31545408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas.
    Jung JT; Kim DH; Kwak EK; Kim JG; Park TI; Sohn SK; Do YR; Kwon KY; Song HS; Park EH; Lee KB
    Ann Hematol; 2006 Sep; 85(9):575-81. PubMed ID: 16673127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.